Search results
Results from the WOW.Com Content Network
Eli Lilly And Co (NYSE: LLY) announced Tuesday a big-ticket acquisition that would mark its foray into gene therapy research.What Happened: Lilly said it has agreed to buy gene therapy company ...
Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa, actively promoting the drug for off-label uses, particularly for the treatment of dementia in the elderly. [258] The $1.415 billion penalty included an $800 million civil settlement, a $515 million criminal fine, and forfeit assets of $100 ...
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market.
Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster ...
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...
Mounjaro was Eli Lilly's best-selling drug in the second quarter with sales of $3.09 billion, a more than threefold increase compared to a year ago. Zebound, meanwhile, was the company's fourth ...
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs ...
(Reuters) -Eli Lilly's weight-loss drug, Zepbound, drastically cut the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the ...